000212515 001__ 212515
000212515 005__ 20240229154913.0
000212515 0247_ $$2doi$$a10.1093/ageing/afac324
000212515 0247_ $$2pmid$$apmid:36702514
000212515 0247_ $$2ISSN$$a0002-0729
000212515 0247_ $$2ISSN$$a1468-2834
000212515 0247_ $$2altmetric$$aaltmetric:142141611
000212515 037__ $$aDKFZ-2023-00200
000212515 041__ $$aEnglish
000212515 082__ $$a610
000212515 1001_ $$aHuemer, Marie-Theres$$b0
000212515 245__ $$aGrip strength values and cut-off points based on over 200,000 adults of the German National Cohort - a comparison to the EWGSOP2 cut-off points.
000212515 260__ $$aOxford$$bOxford Univ. Press$$c2023
000212515 3367_ $$2DRIVER$$aarticle
000212515 3367_ $$2DataCite$$aOutput Types/Journal article
000212515 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675070724_31442
000212515 3367_ $$2BibTeX$$aARTICLE
000212515 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212515 3367_ $$00$$2EndNote$$aJournal Article
000212515 520__ $$aThe European Working Group on Sarcopenia in Older People (EWGSOP) updated in 2018 the cut-off points for low grip strength to assess sarcopenia based on pooled data from 12 British studies.Comparison of the EWGSOP2 cut-off points for low grip strength to those derived from a large German sample.We assessed the grip strength distribution across age and derived low grip strength cut-off points for men and women (peak mean -2.5 × SD) based on 200,389 German National Cohort (NAKO) participants aged 19-75 years. In 1,012 Cooperative Health Research in the Region of Augsburg (KORA)-Age participants aged 65-93 years, we calculated the age-standardised prevalence of low grip strength and time-dependent sensitivity and specificity for all-cause mortality.Grip strength increased in the third and fourth decade of life and declined afterwards. Calculated cut-off points for low grip strength were 29 kg for men and 18 kg for women. In KORA-Age, the age-standardised prevalence of low grip strength was 1.5× higher for NAKO-derived (17.7%) compared to EWGSOP2 (11.7%) cut-off points. NAKO-derived cut-off points yielded a higher sensitivity and lower specificity for all-cause mortality.Cut-off points for low grip strength from German population-based data were 2 kg higher than the EWGSOP2 cut-off points. Higher cut-off points increase the sensitivity, thereby suggesting an intervention for more patients at risk, while other individuals might receive additional diagnostics/treatment without the urgent need. Research on the effectiveness of intervention in patients with low grip strength defined by different cut-off points is needed.
000212515 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000212515 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212515 650_7 $$2Other$$aEuropean Working Group on Sarcopenia in Older People (EWGSOP)
000212515 650_7 $$2Other$$acut-off points
000212515 650_7 $$2Other$$agrip strength
000212515 650_7 $$2Other$$amortality
000212515 650_7 $$2Other$$aprobable sarcopenia
000212515 7001_ $$aKluttig, Alexander$$b1
000212515 7001_ $$aFischer, Beate$$b2
000212515 7001_ $$aAhrens, Wolfgang$$b3
000212515 7001_ $$aCastell, Stefanie$$b4
000212515 7001_ $$aEbert, Nina$$b5
000212515 7001_ $$aGastell, Sylvia$$b6
000212515 7001_ $$aJöckel, Karl-Heinz$$b7
000212515 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b8$$udkfz
000212515 7001_ $$aKarch, André$$b9
000212515 7001_ $$aKeil, Thomas$$b10
000212515 7001_ $$aKemmling, Yvonne$$b11
000212515 7001_ $$aKrist, Lilian$$b12
000212515 7001_ $$aLeitzmann, Michael$$b13
000212515 7001_ $$aLieb, Wolfgang$$b14
000212515 7001_ $$aMeinke-Franze, Claudia$$b15
000212515 7001_ $$aMichels, Karin B$$b16
000212515 7001_ $$00000-0002-3125-7859$$aMikolajczyk, Rafael$$b17
000212515 7001_ $$aMoreno Velásquez, Ilais$$b18
000212515 7001_ $$aPischon, Tobias$$b19
000212515 7001_ $$aSchipf, Sabine$$b20
000212515 7001_ $$aSchmidt, Börge$$b21
000212515 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b22$$udkfz
000212515 7001_ $$aSchulze, Matthias B$$b23
000212515 7001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b24$$udkfz
000212515 7001_ $$aTeismann, Henning$$b25
000212515 7001_ $$aWirkner, Kerstin$$b26
000212515 7001_ $$aDrey, Michael$$b27
000212515 7001_ $$aPeters, Annette$$b28
000212515 7001_ $$00000-0002-5667-6849$$aThorand, Barbara$$b29
000212515 773__ $$0PERI:(DE-600)2065766-3$$a10.1093/ageing/afac324$$gVol. 52, no. 1, p. afac324$$n1$$pafac324$$tAge & ageing$$v52$$x0002-0729$$y2023
000212515 909CO $$ooai:inrepo02.dkfz.de:212515$$pVDB
000212515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000212515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000212515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000212515 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000212515 9141_ $$y2023
000212515 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-08
000212515 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000212515 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000212515 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000212515 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAGE AGEING : 2022$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000212515 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bAGE AGEING : 2022$$d2023-10-24
000212515 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000212515 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000212515 980__ $$ajournal
000212515 980__ $$aVDB
000212515 980__ $$aI:(DE-He78)C020-20160331
000212515 980__ $$aI:(DE-He78)C070-20160331
000212515 980__ $$aUNRESTRICTED